RESUMEN Objetivo. Adaptar y validar el instrumento EMPODERA-TB para medir el empoderamiento en pacientes con tuberculosis pulmonar. Métodos. Se adaptó y validó un instrumento, diseñado inicialmente para medir el empoderamiento en pacientes con enfermedades crónicas, para medir el empoderamiento en pacientes con tuberculosis. Para ello, se seleccionaron y adaptaron los ítems aplicables a los pacientes con tuberculosis. La validación se realizó mediante análisis factorial exploratorio y confirmatorio, y la consistencia interna mediante el coeficiente alfa de Cronbach, con base en los datos de una muestra de 49 pacientes de origen mexicano con diagnóstico de tuberculosis pulmonar. Resultados. El instrumento se integró por 19 ítems agrupados en tres dimensiones: adquisición de conocimientos, habilidades para compartir información y para la toma de decisiones. Se observó un ajuste aceptable (SRMR: 0,124; CD: 0,999), mientras que la consistencia interna para las dimensiones fue de 0,878; 0,879 y 0,808, respectivamente, y para el instrumento completo fue de 0,885. Conclusiones. El instrumento mostró índices de ajuste de bondad aceptables y consistencia interna adecuada, por lo que permite medir el empoderamiento en pacientes con tuberculosis pulmonar. Este instrumento será de utilidad en la práctica clínica y epidemiología de tuberculosis en países latinoamericanos de habla hispana, y permitirá implementar estrategias que mejoren el conocimiento y el apego al tratamiento, así como la interacción con pacientes o individuos en riesgo de contagio y, con ello, establecer estrategias de prevención.

ABSTRACT Objective. Adapt and validate EMPODERA-TB in order to measure empowerment of patients with pulmonary tuberculosis (TB). Methods. An instrument initially designed to measure empowerment of patients with chronic diseases was adapted and validated to measure empowerment of patients with tuberculosis. The items applicable to patients with tuberculosis were selected and adapted. Validation was performed using exploratory and confirmatory factor analysis, and internal consistency was determined using Cronbach's alpha coefficient, based on data from a sample of 49 patients of Mexican origin diagnosed with pulmonary tuberculosis. Results. The instrument comprised 19 items grouped into three dimensions: knowledge acquisition, information-sharing skills, and decision-making skills. Acceptable goodness-of-fit was observed (SRMR: 0.124; CD: 0.999); internal consistency for the three dimensions was 0.878, 0.879, and 0.808, respectively, and for the instrument overall it was 0.885. Conclusions. The instrument showed acceptable goodness-of-fit and adequate internal consistency, making it possible to measure empowerment of patients with pulmonary tuberculosis. This instrument will be useful in TB clinical practice and epidemiology in Spanish-speaking Latin American countries. It will allow implementation of strategies that improve knowledge and adherence to treatment, interactions with patients or individuals at risk of infection, and development of prevention strategies.

RESUMO Objetivo. Adaptar e validar o instrumento EMPODERA-TB para medir o empoderamento em pacientes com tuberculose pulmonar. Métodos. Um instrumento elaborado inicialmente para medir o empoderamento em pacientes com doenças crônicas foi adaptado e validado para medir o empoderamento em pacientes com tuberculose. Para tanto, foram selecionados e adaptados os itens aplicáveis aos pacientes com tuberculose. A validação foi realizada por meio de análise fatorial exploratória e confirmatória, e a consistência interna foi analisada por meio do coeficiente alfa de Cronbach, com base em dados de uma amostra de 49 pacientes de origem mexicana com diagnóstico de tuberculose pulmonar. Resultados. O instrumento foi composto por 19 itens, agrupados em três dimensões: aquisição de conhecimento, habilidade de compartilhar informações e habilidade para a tomada de decisão. Observou-se um ajuste aceitável (SRMR: 0,124; CD: 0,999), enquanto a consistência interna para as dimensões foi de 0,878, 0,879 e 0,808, respectivamente, e para o instrumento como um todo foi de 0,885. Conclusões. O instrumento apresentou índices de bondade de ajuste aceitáveis e consistência interna adequada; portanto, permite mensurar o empoderamento em pacientes com tuberculose pulmonar. Este instrumento será útil para a prática clínica e epidemiológica da tuberculose nos países latino-americanos de língua espanhola, e permitirá a implementação de estratégias que melhorem o conhecimento e a adesão ao tratamento, bem como a interação com pacientes ou indivíduos em risco de contágio e, portanto, o estabelecimento de estratégias de prevenção.

ABSTRACT The purpose of this work was to perform by Whole Genomic Sequencing (WGS) a characterization of tuberculosis isolates circulating in the central region of Veracruz, Mexico, and to determine its geographical distribution. The genome of 25 clinical isolates of tuberculosis patients, recovered from central zone of Veracruz, Mexico, were sequenced and the information obtained was used to characterize lineage, prediction of drug resistance, identification of clonal complexes, and finally correlated with the geolocalization data. Isolates analyzed were included into seven L4 sublineages, most frequent was X3; X1 (4.1.1.3) in 35%. rpoBSer450Leu polymorphism was the most frequently found variant. Sublineage Haarlem (4.1.2) had the widest distribution, found in five municipalities. Of the of two clonal complexes found, the most abundant included eight isolates, with X3/X1 lineage, placed in two municipalities. Combination of WGS and geographic information system was very useful for the identification of sublineages, clonal complexes, and their geographical dispersion with important implications in the epidemiological surveillance and clinical control of TB.

Abstract Background: The state of Veracruz is placed in southeastern Mexico and has a high prevalence of tuberculosis (TB) and drug resistance. Nevertheless, the composition of circulating genotypes in the central region of the state is partially known. Aim: To characterize the genetic diversity of TB in the sanitary jurisdiction V of the state of Veracruz. Methods: A cross-sectional study was conducted among clinical isolates from patients with TB living in the jurisdiction V, in Jalapa Ver., Mexico. Sensitivity to first-line drugs was determined, and genotyping was performed by spoligotyping and MIRU-VNTR 15 loci. Results: Among the 74 isolates analyzed, resistance to one drug was observed in 44 isolates. L4 (EuroAmerican) was the major lineage identified. Five sublineages were the most abundant; H (40%), T (22%), LAM (16%), X (13%) and U (7%). Only 32% of the isolates were clustered by spoligotype and 40% were placed in ten clonal complexes. Conclusions: This is the first description of the genetic structure of TB in the central region of Veracruz. The diversity of genotypes could contribute to its dispersion. This information will be useful for the development of interventions to reduce the impact of TB in the population.

Resumen Antecedentes: El estado de Veracruz se ubica en el sureste de México y presenta una alta prevalencia de tuberculosis (TBC) y drogo resistencia. Sin embargo, la composición de los genotipos circulantes es poco conocida. Objetivo: Caracterizar la diversidad genética de la TBC en la jurisdicción sanitaria V del estado de Veracruz. Métodos: Estudio transversal realizado en aislados clínicos de pacientes con TBC residentes de la jurisdicción V. Se determinó la sensibilidad a medicamentos de primera línea. La genotipificación se realizó mediante espoligotipificación y MIRU-VNTR 15 loci. Resultados: Entre los 74 aislados analizados se observó resistencia a un fármaco en 44 (59%) aislados. Linaje L4 (EuroAmericano) se presentó en 73 aislados. Se identificaron cinco sublinajes; H (40%), T (22%), LAM (16%), X (13%) y U (7%). El 32% de los aislados se agrupó mediante su espoligotipo y 40% en 10 complejos clonales. Conclusiones: Es la primera descripción sobre la estructura genética de TBC en la región central de Veracruz. La diversidad de genotipos podría contribuir a su dispersión en la región. Esta información será útil para el desarrollo de intervenciones y reducir el impacto de TBC en la población.

ABSTRACT The World Health Organization (WHO) places Tuberculosis (TB) as one of the most important health problems today. According to the WHO, this disease requires novel actions to control its expansion and, in this way, achieve one of the goals established in the sustainable development goals: to reduce TB morbidity and incidence by 2030 and regain control. To achieve this goal, the tools currently used for diagnosis and treatment are no longer adequate. In this sense, it is necessary to develop new drugs and vaccines, as well as novel drug administration procedures that generate a better response, reduce times, and optimize treatments. Nanotechnology has incorporated in recent years a considerable number of new tools that significantly increase the diversity of mechanisms for the administration of anti-tuberculosis drugs. Therefore, the present review briefly describes the current state of drug resistance in tuberculosis, as well as the general characteristics of nanoparticles being evaluated as tools to transport new antibiotics against tuberculosis.

RESUMEN La Organización Mundial de la Salud (OMS) ubica a la tuberculosis (TB) como uno de los problemas de salud más preocupantes en la actualidad, y señala que se requieren de acciones novedosas para controlar su expansión y, de esta manera, alcanzar una de las metas establecidas en los Objetivos de Desarrollo Sostenible: reducir para 2030 la morbilidad e incidencia de TB. Para lograr este objetivo, está claro que las herramientas empleadas actualmente para su diagnóstico y tratamiento ya no son las adecuadas. En este sentido, es necesario desarrollar nuevos medicamentos y vacunas, así como novedosos procedimientos de administración de fármacos que generen una mejor respuesta, disminuyan el tiempo y optimicen los tratamientos. La nanotecnología ha incorporado en los últimos años un gran número de nuevas herramientas que incrementan considerablemente, la diversidad de mecanismos para la administración de tratamientos antituberculosos. Dicho esto, la presente revisión describe brevemente el estado actual de la farmacorresistencia en TB, así como las características generales de las nanopartículas que están evaluándose como herramientas para transportar antibióticos antituberculosos.

ABSTRACT The World Health Organization (WHO) places Tuberculosis (TB) as one of the most important health problems today. According to the WHO, this disease requires novel actions to control its expansion and, in this way, achieve one of the goals established in the sustainable development goals: to reduce TB morbidity and incidence by 2030 and regain control. To achieve this goal, the tools currently used for diagnosis and treatment are no longer adequate. In this sense, it is necessary to develop new drugs and vaccines, as well as novel drug administration procedures that generate a better response, reduce times, and optimize treatments. Nanotechnology has incorporated in recent years a considerable number of new tools that significantly increase the diversity of mechanisms for the administration of anti-tuberculosis drugs. Therefore, the present review briefly describes the current state of drug resistance in tuberculosis, as well as the general characteristics of nanoparticles being evaluated as tools to transport new antibiotics against tuberculosis.

RESUMEN La Organización Mundial de la Salud (OMS) ubica a la tuberculosis (TB) como uno de los problemas de salud más preocupantes en la actualidad, y señala que se requieren de acciones novedosas para controlar su expansión y, de esta manera, alcanzar una de las metas establecidas en los Objetivos de Desarrollo Sostenible: reducir para 2030 la morbilidad e incidencia de TB. Para lograr este objetivo, está claro que las herramientas empleadas actualmente para su diagnóstico y tratamiento ya no son las adecuadas. En este sentido, es necesario desarrollar nuevos medicamentos y vacunas, así como novedosos procedimientos de administración de fármacos que generen una mejor respuesta, disminuyan el tiempo y optimicen los tratamientos. La nanotecnología ha incorporado en los últimos años un gran número de nuevas herramientas que incrementan considerablemente, la diversidad de mecanismos para la administración de tratamientos antituberculosos. Dicho esto, la presente revisión describe brevemente el estado actual de la farmacorresistencia en TB, así como las características generales de las nanopartículas que están evaluándose como herramientas para transportar antibióticos antituberculosos.

Tuberculosis (TB) is an infectocontagious respiratory disease caused by members of the Mycobacterium tuberculosis complex. A 7 base pair (bp) deletion in the locus polyketide synthase (pks)15/1 is described as polymorphic among members of the M. tuberculosis complex, enabling the identification of Euro-American, Indo-Oceanic and Asian lineages. The aim of this study was to characterise this locus in TB isolates from Mexico. One hundred twenty clinical isolates were recovered from the states of Veracruz and Estado de Mexico. We determined the nucleotide sequence of a ± 400 bp fragment of the locus pks15/1, while genotypic characterisation was performed by spoligotyping. One hundred and fifty isolates contained the 7 bp deletion, while five had the wild type locus. Lineages X (22%), LAM (18%) and T (17%) were the most frequent; only three (2%) of the isolates were identified as Beijing and two (1%) EAI-Manila. The wild type pks15/1 locus was observed in all Asian lineage isolates tested. Our results confirm the utility of locus pks15/1 as a molecular marker for identifying Asian lineages of the M. tuberculosis complex. This marker could be of great value in the epidemiological surveillance of TB, especially in countries like Mexico, where the prevalence of such lineages is unknown.

INTRODUÇÃO: A situação da tuberculose (TB) foi modificada pelo vírus da imunodeficiência humana (HIV). Com isso, aumentou-se a ocorrência de novos casos de TB e a geração de cepas resistentes à droga, afetando não só as pessoas infectadas com HIV, mas também seus contatos próximos e da população em geral, gerando um sério problema de saúde pública. No entanto, a magnitude dos fatores associados à esta coinfecção diferem consideravelmente em relação aos grupos populacionais e áreas geográficas. MÉTODOS: Para avaliar a prevalência da comorbilidade e fatores de risco da coinfecção de tuberculose (TB) em uma população com o vírus da imunodeficiência humana (VIH+) no sudeste do México, nós fizemos a análise das variáveis clínicas e epidemiológicas e de isolamento da micobactérias através de cultura de amostras respiratórias. RESULTADOS: A partir de 147 indivíduos HIV+ analisados, 12 foram positivos na cultura, o que mostra uma prevalência de 8% para a coinfecção. A única variável com significância estatística encontrada para a coinfecção foi o número de células CD4-T<200 células/mm³, OR 13 (95%, CI 2-106 vs 12-109). CONCLUSÕES: Ao nosso conhecimento este é o primeiro relatório que descreve os fatores associados à coinfecção de tuberculose com HIV em uma população do sudeste do Mexico. O baixo número de células T CD4+ foi à única variável associada com a coinfecção por TB no resto das variáveis, proporcionando situações que exigem intervenções específicas e particulares para este grupo populacional.

INTRODUCTION: The situation of tuberculosis (TB) is being modified by the human immunodeficiency virus (HIV), which is increasing the occurrence of new cases and the generation of drug resistant strains, affecting not only the people infected with HIV, but also their close contacts and the general population, conforming a serious public health concern. However, the magnitudes of the factors associated to this co-infection differ considerably in relation to the population groups and geographical areas. METHODS: In order to evaluate the prevalence and risk factors for the co-infection of tuberculosis (TB) in a population with human immunodeficiency virus (HIV+) in the Southeast of Mexico, we made the analysis of clinical and epidemiological variables and the diagnosis of tuberculosis by isolation of mycobacteria from respiratory samples. RESULTS: From the 147 HIV+ individuals analyzed, 12 were culture positive; this shows a prevalence of 8% for the co-infection. The only variable found with statistical significance for the co-infection was the number of CD4-T < 200 cells/mm³, OR 13 (95%, CI 2-106 vs 12-109). CONCLUSIONS: To our knowledge this is the first report describing the factors associated with tuberculosis co -infection with HIV in a population from Southern Mexico. The low number of CD4 T-cells was the only variable associated with the TB co-infection and the rest of the variables provide scenarios that require specific and particular interventions for this population group.